ClinicalTrials.gg

Program

evobrutinib

Also written as “Evobrutinib”, “M2951” and “MSC2364447C”.

Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Lupus Erythematosus, Systemic · Arthritis, Rheumatoid · Autoimmune Diseases, led by Merck KGaA, Darmstadt, Germany.

Furthest: phase 3, since Jul 23, 201920 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck KGaA, Darmstadt, Germany200 open or runningphase 3since Jul 23, 2019Aug 28, 2015none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Aug 28, 2015.

  1. May 24, 2016Phase 2 study in Arthritis, RheumatoidNCT02784106 · 65 enrolled · United States, Germany
  2. Nov 23, 20162 phase 2 studiesNCT02975349, NCT02975336
  3. Jul 25, 2017Phase 2 study in Arthritis, RheumatoidNCT03233230 · 390 enrolled · United States, Argentina, Bulgaria and more
  4. Feb 6, 2018Phase 1 study in Renal InsufficiencyNCT03436394 · 31 enrolled · Germany
  5. Oct 29, 2018Phase 1 study in HealthyNCT03725072 · 6 enrolled · Netherlands
  6. Apr 29, 2019Phase 1 study in HealthyNCT03934502 · 20 enrolled · Germany
  7. Jul 23, 20192 phase 3 studies in Multiple Sclerosis, Relapsing-RemittingNCT04032171, NCT04032158
  8. Mar 17, 2020Phase 1 study in HealthyNCT04314024 · 18 enrolled · Germany
  9. Apr 6, 20202 phase 3 studies in Relapsing Multiple SclerosisNCT04338061, NCT04338022
  10. Sep 10, 2020Phase 1 study in Hepatic ImpairmentNCT04546789 · 24 enrolled · Germany
  11. Jan 4, 2021Phase 1 study in Autoimmune DiseasesNCT04697511 · 16 enrolled · Germany
  12. Sep 23, 2021Phase 1 study in HealthyNCT05064488 · 40 enrolled · Germany
  13. Jan 13, 20222 phase 1 studies in HealthyNCT05248945, NCT05245396
  14. Oct 8, 20252 phase 1 studies in HealthyNCT07214935, NCT07214922

TargetBeta

BTK →read by rule
“An inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07214935Healthy · Germany1CompletedAug 25, 202336
NCT07214922Healthy · Germany1CompletedFeb 24, 202328
NCT05245396Healthy · United Kingdom1CompletedFeb 14, 202358
NCT05248945Healthy · Germany1CompletedJul 18, 202214
NCT05064488Healthy · Germany1CompletedDec 10, 202140
NCT04697511Autoimmune Diseases · Germany1CompletedFeb 25, 202116
NCT04546789Hepatic Impairment · Germany1CompletedMay 16, 202124
NCT04338061Relapsing Multiple Sclerosis · United States, Belarus, Brazil and more3TerminatedOct 2, 20231,166
NCT04338022Relapsing Multiple Sclerosis · United States, Argentina, Australia and more3TerminatedOct 2, 20231,124
NCT04314024Healthy · Germany1CompletedJun 23, 202018
NCT04032171Multiple Sclerosis, Relapsing-Remitting · United States, Germany3TerminatedMay 20, 20201
NCT04032158Multiple Sclerosis, Relapsing-Remitting · United States, Germany3TerminatedApr 16, 20203
NCT03934502Healthy · Germany1CompletedJun 12, 201920
NCT03725072Healthy · Netherlands1CompletedDec 5, 20186
NCT03436394Renal Insufficiency · Germany1CompletedFeb 22, 201931
NCT03233230Arthritis, Rheumatoid · United States, Argentina, Bulgaria and more2CompletedSep 23, 2019390
NCT02975349Multiple Sclerosis, Relapsing-Remitting · Bulgaria, Czechia, Poland and more2TerminatedJan 24, 2018267
NCT02975336Lupus Erythematosus, Systemic · United States, Argentina, Bulgaria and more2TerminatedNov 27, 2019469
NCT02784106Arthritis, Rheumatoid · United States, Germany2CompletedApr 30, 201765
NCT02537028Lupus Erythematosus, Systemic · United States, Bulgaria1CompletedOct 4, 201624

How it is read

Names in the registry

  • “Evobrutinib”, 12 entries
  • “M2951”, 7 entries
  • “MSC2364447C”, 2 entries
  • “Treatment A”, 1 entry
  • “Treatment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.